Two monoclonal antibody groups were prepared from adult human atrial and ventricular myosin heavy chains. Using these two groups, we were able to identify two myosin variants in human atria and to classify human atrial fibers into a-, mixed, or /S-fibers according to the reactivity of the two monoclonal antibody groups to a-and /-myosin heavy chains of normal young and hypothyroid rat ventricles, respectively. The a-fiber percentage of the left atria in two normal human hearts was 15% higher than in the right atria. The auricles contained two to three times more a-fibers than /3fibers, whereas the proportion was reversed in the crista terminalis. The mean fiber diameter of the aand /-fibers was 13.6 + 3 gm. A complete a-to /-fiber transition was observed in all atrial regions of two hearts with severe ventricular myocardial infarction; a moderate a-to /3-fiber transition was observed only in the left atria of two hearts with primary congestive cardiomyopathy. The mean diameters of the two fiber types were significantly increased in all diseased hearts (1 9 ± 3.8 ,gm). We hypothesize that pressure overload and increased wall tension successively induce an enlargement of the fiber diameter and an a-to /3-myosin transition.
AT LEAST TWO molecular variants of myosin heavy chains have been identified in normal human atrial myocardium by histochemical and indirect immunofluorescence studies involving polyclonal and monoclonal antibodies.>1 We have referred to the human atrial myosin, which reacts strongly with one set of our monoclonal antibodies, as "/3-like" atrial myosin since this set of monoclonal antibodies strongly reacts with ventricular,8-myosin in hypothyroid rats.3 This human atrial :-like myosin variant has been separated from the other myosin form by immunochromatography, and it has been shown that each form of human atrial myosin has a different primary structure but the same high enzymatic activity in vitro. 5 No direct evidence concerning any immunologic cross-reactivity of the other human atrial myosin with rat ventricular a-myosin is available at present. The fibers containing either /3-like myosin or the other myosin form are not randomly distributed within the different regions of the atria in normal hearts, and marked changes in their local distributions have been described in diseased human hearts. 2 3 Neither the distribution of the two fiber types in the different atrial regions nor their pathologic modifications have ever been quantified.
In this study we used, for the first time, two groups of monoclonal antibodies that specifically detect each atrial myosin variant in the rat heart as well as in the human heart. We also quantified the fiber type distributions within different regions of the atria in two normal and four diseased human hearts. In the latter, different isomyosin distributions were shown to be related to different pathologic conditions.
Materials and methods
Patients. Four adult human hearts were obtained from three recipients of cardiac transplants (denoted as hearts A, B, and C) (Cardiological Hospital of Lyon) and from a patient who died at the coronary care unit (denoted as heart D) (Cardiological Department, St. Eloi Hospital, Montpellier). The atria from these hearts were compared with the atria from two 16- year-old boys who died in traumatic accidents (denoted as hearts NI and N2) (Nephrology and Urology Departments, Hospital St. Charles, Montpellier). Informed consent was obtained from the patients or from the patients' families.
Patients A and B had primary congestive cardiomyopathies.
They underwent heart transplantation because of progressive heart failure despite maximum dosages of digitalis, diuretics, and vasodilators. Patient C had two myocardial infarctions (13 years and 1 year before transplantation) involving, as seen on gross examination, the posterior basal wall and the posterior papillary muscle of the left ventricle. While waiting for a suitable donor, patient C developed a congestive heart failure that was treated with digoxin, a diuretic, and a vasodilator, but his health continued to deteriorate rapidly. No cardiac catheterization was performed before heart transplantation. Patient D had a massive anterior apical myocardial infarction at the age of 47. A ventricular aneurysmectomy was performed 11 years after infarction. He died at the hospital from heart failure. His medications included digoxin, furosemide, isosorbide dinitrate, and amiodarone. The last medication was required because of numerous premature ventricular beats. Shortly before death, a hyperthyroid function was diagnosed. Clinical data for the four patients are summarized in table 1. Preparation of tissue. Hearts from patients A, B, and C were immediately weighed and examined after their removal. The three other hearts were obtained within 2 hr after death. If available, at least seven different tissue samples were excised from the following areas of the atria: three samples from the right atrium (auricle, anterior trabeculated wall, and crista terminalis), three samples from the left atrium (auricle, posterior and superior free wall), and a sample from the interatrial septum. Because of cardiac transplantation requirements, only four atrial samples were excised from each of the three recipients' hearts (hearts A, B, and C) and compared with homologous regions of the heart obtained at necropsy (heart D) and with the two normal hearts (hearts Nl and N2). All atrial samples were frozen within 3 hr after death.
Experimental model. Normal Wistar rats (6 weeks old) and hypothyroid rats from the same strain (5 mg of propylthiouracil forcibly fed daily for 4 weeks) were killed by a sharp blow on the neck. The hearts were rapidly removed, and the samples were excised and processed like the human samples. These animals were chosen because, according to Hoh et al.,6 the normal young rat ventricle is mainly composed of a-myosin heavy chain, whereas the hypothyroid rat ventricle is mainly composed of fi-myosin heavy chain.
Monoclonal antibodies. Human ventricular myosin and one of the human atrial myosins were successively used as immunogens to obtain different populations of antimyosin monoclonal antibodies. The ventricular myosin used as an immunogen for the first generation of monoclonal antibodies was extracted from the left ventricle of a 53-year-old woman who had a hypertrophic obstructive cardiomyopathy. Mice immunization, fusion, screening, and cloning of the hybridoma cell cultures have been described in detail elsewhere.3 By indirect immunofluorescence, it has been observed that some of these antiventricular myosin monoclonal antibodies react heterogeneously with the atrial fibers of normal human hearts.3 Furthermore, a few of them react strongly with the ventricular fibers of hypothyroid rat hearts, which mainly contain the fl-type ventricular myosin heavy chain,3 and react weakly or not at all with the ventricular fibers of normal young rat hearts. This set of monoclonal antibodies, which are specific for the fl-type rat ventricular myosin and react with one of the human atrial myosins, are hereafter referred to as anti-fl Mab. To further check the specificity of the antibodies, total muscle extracts of normal and hypothyroid rat ventricles were first purified by sodium dodecyl sulfate polyacrylamide gel electrophoresis and then blotted on nitrocellulose paper. After incubation with anti-,f Mab, the immune band was revealed by rabbit antimouse immunoglobulin G coupled with peroxidase. [3] [4] [5] Atrial myosin was prepared from a fraction of the left atrium of a normal patient (N1) and applied on afflnity columns with one of the anti-fl Mab.s The atrial myosin fraction that did not react with the anti-f Mab did not fix to the column and was used as an immunogen to produce the second population of monoclonal antibodies. The same procedures as above3 were used for production of hybridoma. A few of the resulting antibodies were selected according to their cross-reactivity with the ventricular fibers of a normal rat, which mainly contain a-type ventricular myosin heavy chains; these monoclonal antibodies are hereafter referred to as anti-a Mab (see Results). The specificity of this group of antibodies was also verified by immunoblots.
Immunofluorescence. Tissue samples were kept frozen at -80°C until used. Sections (4 to 6 gim) were cut in a cryostat at -200 C. Indirect immunofluorescence was performed according to the method of Gorza et al.7 with fluorescein-or rhodamine-labeled rabbit antimouse IgG specially prepared to avoid nonspecific cross-reaction with human tissue (Nordic Immunological Laboratories, Tilburg, The Netherlands). Some anti-,f Mab were coupled to fluorescein isothiocyanate8 (FITC) (Nordic Immunological Laboratories). For indirect/direct immunofluorescence labeling, sections were processed for indirect immunofluorescence as usual, then the sections were adsorbed with 1/10 diluted nonimmune mouse serum for 30 min at 370 C. After a 5 min wash with phosphate-buffered saline (PBS), an FITC-coupled monoclonal antibody was added and sections were incubated for 30 min at 370 C. The sections were rinsed 10 min with two changes of PBS, then 10 min with 2% PBSformaldehyde, and were finally mounted. The incubation with nonimmune mouse serum was performed to block excess rabbit antimouse binding sites.9 Sections were examined under a Leitz Orthoplan microscope with epifluorescence optics equipped with Ploemopak filter sets containing specific filter combinations for fluorescein and rhodamine. Controls of immunofluorescence were performed by successively omitting one of the steps in the procedures or by incubating sections with a cell culture supernatant either without monoclonal antibodies or containing an antibody to renin (a generous gift from B. Pau). These controls enabled us to verify the absence of any contaminating cross-reactions.
Fiber counting. To quantitate variations in the proportion of the different fiber types detected by each population of monoclonal antibodies within the different regions of the normal atria, we arbitrarily formed three groups of fibers according to their isomyosin content: a-fibers, mixed. and 3-fibers (see Results). A point-counting method with a test grid'0 was carried out on photomicrographs of randomly selected areas within well-defined atrial regions. We counted the different fiber-type contents in 10 to 20 nonserial sections of the same tissue region. This method was repeated on each sample from the normal and diseased hearts. The difference between the percentages of each fiber group on repeated measurements by two trained observers was less than 10%.
Morphometry. The fiber diameter of atrial cells was measured on photomicrographs of cross and oblique sections of myocardial cells (magnification x 200). When oblique sections were used, the shortest diameter of the fiber profile was measured. Fiber diameters were measured on four to 10 nonserial sections of each tissue sample. More sections were needed for a-fibers in the auricles of hearts C and D because these fibers were extremely rare.
Statistical analysis. Student's t test for unpaired data was used. Data are expressed as mean + SD.
Results
Specificity of monocional antibodies. The two groups of monoclonal antibodies were raised in mice injected either with adult human ventricular myosin3 or with one of the adult human atrial myosins purified by affinity chromatography with an antihuman ventricular myosin monoclonal antibody.5 Preliminary immunoreplicate or immunofluorescence experiments were made to select, from among the numerous monoclonal antibodies available after each fusion, those that differentially reacted on normal young rat ventricles mainly containing a-myosin heavy chain, as opposed to hypothyroid rat ventricles mainly containing 3-myosin heavy chains. This classification corresponds to the terminology adopted by Hoh et al. 6 for designating the two types of myosin heavy chains present in rat ventricles. Thus, according to the results of immunoblotting experiments, monoclonal antibodies strongly reacting with normal young rat myosin heavy chains and reacting poorly or not at all with hypothyroid rat myosin heavy chains were selected and referred to as anti-a Mab. Similarly, the monoclonal antibodies strongly reacting with hypothyroid rat myosin heavy chains and reacting poorly or not at all with normal young rat myosin heavy chains were selected and referred to as anti-f Mabl3-5(data not shown). The group of anti-a Mab used in the immunofluorescence experiments reacted strongly and homogeneously with the ventricular fibers of normal young rat hearts but poorly and heterogeneously with those of hypothyroid rat hearts (figure 1, a and c); the group of anti-,( Mab reacted in a complementary way with the anti-a Mab group in both types of rat ventricle (figure 1. b and d). At all antibody dilutions, many fibers in the hypothyroid rat ventricle did not react at all with the anti-a Mab (figure 1,) whereas many fibers in the normal young rat hearts did not react at all with the anti-,8 Mab ( figure 1, b) . These results indicate that the anti-a and the anti-fl Mab did not cross-react with either the fl-or the a-myosin heavy chains, respectively. Any fiber strongly stained with the anti-a Mab but not reacting with the anti-fl Mab consequently does not contain fi-myosin heavy chains and is referred to here as an a-fiber. Similarly, any fiber strongly stained with the anti-fl Mab but not reacting with the anti-ae Mab is referred to here as ,Bfiber. Some other fibers in the hypothyroid rat ventricles and in the normal young rat ventricles were stained at various immunofluorescent levels with either the anti-a or the anti-fl Mab, respectively, whereas they were all strongly stained with either the anti-fl or the anti-a Mab, respectively; these fibers are referred to here as mixed fibers since they apparently contained variable amounts of a-and fi-myosin heavy chains (if not other). Normal human atria. Most of the monoclonal antibodies so selected in each hybridoma group reacted in a heterogeneous way with transverse sections of normal human atrial fibers in regions previously known for their myosin heterogeneity.3 The specificity of the two groups of antibodies permitted a classification of human atrial fibers according to their myosin content. Figure 2 shows an atrial section of the posterior free wall of a normal human left atrium (patient NI), indirectly stained with an anti-a Mab and rhodamine then further stained with an anti-fl Mab coupled to fluorescein. As with the rat ventricles, the human atrial fibers that were intensely stained with the anti-a Mab (arrowhead in figure 2, a) but not with the anti-fl Mab (arrowhead in figure 2, b ), were called a-fibers since they presumably contained only the a-like type of human atrial myosin. Conversely, the human atrial fibers that were not reactive with the anti-a Mab (arrow in figure  2 , a) but were intensely stained with the anti-fl Mab (arrow in figure 2, b ) were called f-fibers since they presumably contained only fl-like human atrial myosin. Besides these extreme situations, a significant number of human atrial fibers were intermediately stained with both antibody groups. These atrial fibers, hereafter denoted as mixed fibers, presumably contained a mixture of the ca-and fl-like human atrial myosin. It should be noted that some fibers that were strongly and equally stained with one type of antibody (see fibers in the top left corner of figure 2, a) exhibited different degrees of intermediate staining with the other type of antibody ( figure 2, b) . This was observed repeatedly on sections from different samples of normal atria. The anatomic description of atrial myosin distribution in normal human hearts, previously made with the anti-fl Mab,3 was corroborated in this study by the antia Mab. We also attempted a quantification of the percentages of a-and fl-fibers contained in limited areas randomly selected within the atria, using a point-counting method.'0 Of the total fibers in the atrial areas studied in the two normal hearts, 20% to 35% were mixed and at present are not classifiable as either a-or f-fiber types. Within this limitation and the 10% margin of error observed for the quantitation measurements, a mean fiber distribution corresponding to a balanced number of a-and /8-fibers, roughly 40% each, was observed over large regions of normal left and right atria. Slight variations around this mean fiber distribution were observed in some regions in the left and right atria and in the interatrial septa. The total number of a-fibers was about l5C/% less in the right atria than in the left, and no significant individual variation was observed. The most extreme fiber distributions were observed in both auricles and in the crista terminalis of the right atrium; the /3-fiber content in both auricles was about 18%, whereas the a-fiber content was more than 45%. The 3-fiber content of the crista terminalis in the right atrium was about 50%, while the a-fiber content was 20%. Figure 3 and table 2 present these "typical" fiber distributions. The measurements of the mean fiber diameter indicated that the diameters of the a-and /3-fibers were roughly the same in all atrial regions (table 3) .
Diseased human hearts. The same two groups of monoclonal antibodies applied to atrial sections from the four diseased human hearts allowed the same fiber classification into a-, mixed, and /3-fibers as in the normal hearts. The same method of quantitating the different fibers indicated a significant increase in the percentages of the /3-fibers in the atria of the four diseased hearts. Moreover, the diseased hearts could be separated into two groups according to their fiber distributions and according to their pathologic history. The left atria from hearts A and B with primary congestive cardiomyopathy showed a significant and similar increase in their /3-fiber content. Their mean fiber distribution roughly corresponded to an a-fiber content of 25%, mixed fibers 15%, and 3-fibers 60%, which was significantly different from the mean distributions observed in both normal hearts ( figure 4 and  table 2 ). The interatrial septa also showed this shift to an increased /3-fiber content. Curiously, the left auricles and the anterior walls of the right atria of hearts A and B contained the same fiber distributions as the corresponding atrial regions in both normal hearts. Atria from the ischemic hearts C and D exhibited a dramatic shift in their fiber distribution, since all atrial regions had fiber distributions corresponding to 98% to 100% /3-fibers ( figure 4 and table 2 ). For example, the fiber most reactive with the anti-a Mab (figure 5, a, arrow) is the unique weakly reactive fiber on the serial section processed with the anti-,3 Mab ( figure 5, b,   arrow) . Surprisingly, some of these atrial fibers still exhibited various degrees of fluorescence after labeling with the anti-a Mab, although they did not differ with respect to brightness after labeling with the anti-,/3
Mab. The mean fiber diameters were the same in the four diseased hearts and did not differ between the aand /3-fibers. However, the fiber diameters of the diseased atria were significantly larger than those of the atrial fibers in the two normal hearts (table 4) .
Discussion
On the basis of the results presented here and in three recent articles,' one can postulate that normal human atria contain at least two types of structurally n values refer to the number of measurements made on each atrial specimen.
AMean diameter of cxand /-fibers in all regions together. different myosin heavy chains, each immunologically related to the oz-and /-myosin heavy chains detected in the ventricular myocardia of normal young and hypothyroid rats,6 respectively. This a-and ,8-like classification of myosin heavy chains within human atria clearly results from the specificity of the two groups of monoclonal antibodies used; these results extend the previous histochemical and immunologic observations of myosin heterogeneity within human atria.' 2 We know that hurman atrial and ventricular /3-myosins have different light and heavy chains and different enzymatic activities in vitro.5 The relationship between the structures of the oz-myo5in heavy chains present in human atria and ventricles is still unknown, although the two human cardiac myosins have different light chains.5 To summarize, in human atria as well as in human ventricles,l-5' l and more generally in the atria and ventricles of most mammalian hearts (for a review see refs. 12 and 13), two different genes that code for a-and /3-myosin heavy chains can be expressed.
The availability of monoclonal antibodies that react specifically to each atrial myosin heavy chain type makes it feasible to classify at least 70% of the total atrial fibers into pure a-or /-myosin-containing fibers and to study isomyosin transition within human hearts. With both sets of antibodies it is possible to detect the simultaneous presence of the two types of atrial myosin heavy chains within a fiber on serial sections and to evaluate its content in terms of myosin types. As previously suggested by Schiaffino et al.'4 and demonstrated here, the strong reactivity of an atrial fiber with an antibody specific for the a-or /3-heavy chain, for example, cannot be taken as an indication that this particular fiber contains only the a-or /3-heavy chain.
Our use of antibodies specific for a-myosin heavy chain shows that the same fibers in fact contain some amounts of a-myosin heavy chain (see figure 5 ). The Vol. 72, No. 2, August 1985 availability of two specific populations of monoclonal antibodies, together with the high sensitivity of immunofluorescence in detecting myosin components, finally enables us to monitor isomyosin transition within individual muscle fibers. The presence of a third myosin heavy chain, immunologically related to the previously described human atrial a-and /-myosin heavy chains, cannot be totally excluded by the present experiments. This situation has already been described in normal rat'5 16 and human ventricles.' Additional experiments are needed to verify this hypothesis.
The second conclusion of our study concerns the quantification of local fiber changes. These regional fiber variations with regard to their myosin content have already been demonstrated within human and bovine atria by polyclonal or monoclonal sera specific for the /3-myosin heavy chains.2 3'7 However, the fiber distributions observed in the two human atrial studies differ in large regions of the left atrium and interatrial septum. With our dual monoclonal antibody system, we observed that a very balanced mixture of a-and /3fibers characterizes the overall mean fiber distribution in both atria and in the interatrial septa of normal human hearts, whereas the right atrium contains roughly 15% more /3-fibers than the left atrium. In contrast, Gorza et al.,2 using polyclonal antibodies that did not detect atrial ce-fibers in normal human hearts, indicated that atrial fibers staining for the /3-myosin heavy chains were rare in the left atrium and particularly abundant in the right atrium and the interatrial septum. These apparent quantitative discrepancies with respect to the regional distributions of myosin types in the human atrium could be caused by the complexity of LEFT ATRIUM 100. the mixture of polyclonal immunoglobulins; the mixture was raised from myosin prepared from human skeletal pectoralis muscle and absorbed on bovine left atrial myosin, and both myosin preparations were a mixture of different myosin types. 7 17 In our study, additional cross-reactivities resulting from the use of different animal species or muscles as immunogens have been partially avoided in each antibody group, since the antibodies were prepared from human ventricular myosin or from a purified fraction of human atrial myosin. Only a quantitative determination of the myosin content within each fiber would resolve these discrepancies.
The local changes in distribution of atrial fiber types and their quantification within four diseased human hearts provide new information on the possible physiologic meaning of the local expression of atrial a-and ,B-myosin genes. These four atria, all of which had a hemodynamic pressure overload, contained significantly more /-fibers than did the normal human atria. This transition from a-to /-myosin heavy chains has TABLE 4 Comparison of the diameters of a-and /3-fibers (mean hearts (A, B, C, and D) been described previously in the hypertrophic ventricles of many animal hearts that have been experimentally submitted to a volume-pressure overload, and recently in diseased human hearts.2 Curiously, this myosin-type transition in response to sustained mechanical or hormonal stress has not, to date, been detected in animal atria.`In our study the levels and the localizations of the atrial myosin transitions in hearts A and B were different from those in hearts C and D. The at-to -fiber transition was nearly complete in all atrial regions of hearts C and D, which sustained ventricular myocardial infarctions. In contrast, a moderate but significant increase in the /3-fiber content, compared with that of normal atria, was observable only in the left atria (minus the left auricles), and not in the right atria of hearts A and B, which had congestive cardiomyopathies. These differences in the myosin gene expression are presumably related to pathologic differences between the four hearts. Patients A and B differed in cardiac characteristics from patients C and D; patients C and D had murmurs from mitral insuffi- 
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CIRCULATION ciency and their left atria were larger, as observed by echocardiography. On the other hand, patients A and B had heavier hearts. The difference in the pathogenesis of cardiac overload explains the heavier hearts in patients A and B; the large scars of ventricle necrosis in hearts C and D were responsible for the relatively smaller increase in heart weight. The difference in pathogenesis is presumably not involved in the /3-fiber transition; the atria of hearts C and D as well as those of hearts A and B were free of necrosis. The main pathologic difference between the atria of the hearts A and B and those of hearts C and D is presumably a difference in the tension of the atrial walls. Considering that wall tension increases with the diameter of the cavity, at constant pressure, we can assume that the tension of the atrial walls in hearts C and D was higher than that in hearts A and B (table 1). We finally hypothesize that the local increase in the expression of the atrial /3myosin gene results from the difference in the tension of the atrial wall. We have already proposed the same hypothesis to explain the low /3-fiber content observed in the auricles of normal human hearts that had the same inner pressure as the rest of the atrium but a smaller diameter.3 Patient D, who underwent longterm therapy with amiodarone and had hyperthyroidism, had the same atrial fiber pattern as patient C. Although no data are available on the effect of dysthyroidism or amiodarone on isomyosin distribution in human hearts, we could expect an effect since these features can modify the myosin gene expression in animal ventricles.6 "9
Finally, it is interesting to note that the atrial myosin transition observed in the diseased human hearts did not coincide with the increase in diameter observed in the corresponding fibers. Under hemodynamic pressure overload, atrial fibers, like ventricular fibers, increase in size; this increase in intracellular organelles corresponds in part to an increase in the production of myofibrils.20 The absence of significant differences in the mean atrial fiber diameter in the four diseased hearts supports the view that a maximum adaptation of this feature had been reached. However, hearts C and D, which sustained greater increases in wall tension, exhibit a larger ato /3-fiber transition than hearts A and B. Thus, one can hypothesize that among the many adaptive processes induced by cardiac overload, there is a quantitative adaptation, i.e., an increase in the production of myofibrils, followed by a qualitative adaptation, i.e., a transition from ato /3-myosin heavy chains. For this reason, it is impossible to predict the isomyosin composition of a fiber according to its diameter. The increase in fiber diameter preceding Vol. 72, No. 2, August 1985 the myosin-type transition in the diseased human hearts suggests a further concomitant use of these two markers in evaluating the timing of the adaptive process involved in these cardiac diseases.
